After hosting investor meetings with management, Piper Jaffray analyst William Quirk believes Myriad Genetics (MGN) is “on the cusp of several positive news events.” Management is optimistic that they could get a draft local coverage determinations for expanded GeneSight coverage by Medicare, Quirk tells investors in a research note. He expects visibility on this by late March. Further, the analyst believes Counsyl’s April 1 in-network status with UnitedHealth (UNH) could lead to $6M-$7M upside to his current Q4 estimates. Quirk reiterates an Overweight rating on Myriad Genetics with a $47 price target.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.